News
LMAT
84.53
-1.37%
-1.17
Zacks.com featured highlights include Life Time, Cardinal Health, LeMaitre Vascular and Flowserve
NASDAQ · 3d ago
4 Stocks With High Coverage Ratios Offer Safer Bets Going Into 2026
NASDAQ · 4d ago
Weekly Report: what happened at LMAT last week (1124-1128)?
Weekly Report · 4d ago
Dividend Champion, Contender, And Challenger Highlights: Week Of November 30
Seeking Alpha · 6d ago
1 Reason LMAT is Risky and 1 Stock to Buy Instead
Barchart · 11/28 08:56
LeMaitre (LMAT) Q3 2025 Earnings Call Transcript
NASDAQ · 11/27 22:56
Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now
NASDAQ · 11/27 17:45
Wells Fargo Remains a Hold on Lemaitre Vascular (LMAT)
TipRanks · 11/26 12:27
Weekly Report: what happened at LMAT last week (1117-1121)?
Weekly Report · 11/24 09:09
3 Healthcare Stocks We Steer Clear Of
Barchart · 11/24 07:52
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
Barchart · 11/21 18:00
Ex-Dividend Reminder: CenterPoint Energy, Regeneron Pharmaceuticals and LeMaitre Vascular
NASDAQ · 11/18 15:01
Weekly Report: what happened at LMAT last week (1110-1114)?
Weekly Report · 11/17 09:09
Dividend Champion, Contender, And Challenger Highlights: Week Of November 16
Seeking Alpha · 11/14 23:34
New Strong Buy Stocks for November 14th
NASDAQ · 11/14 11:48
Analysts Anticipate PFM Will Reach $58
NASDAQ · 11/13 11:41
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
NASDAQ · 11/11 17:45
Weekly Report: what happened at LMAT last week (1103-1107)?
Weekly Report · 11/10 09:08
LeMaitre Vascular’s Earnings Call: Growth Amid Challenges
TipRanks · 11/08 00:03
LeMaitre Vascular Price Target Cut to $93.00/Share From $97.00 by Wells Fargo
Dow Jones · 11/07 19:06
More
Webull provides a variety of real-time LMAT stock news. You can receive the latest news about Lemaitre Vasculr through multiple platforms. This information may help you make smarter investment decisions.
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.